Ensysce Biosciences Inc (NASDAQ:ENSC) has a beta value of 0.84 and has seen 1.49 million shares traded in the last trading session. The ENSC stock price is -1111.76% off its 52-week high price of $2.06 and 0.0% above the 52-week low of $0.17. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.46 million shares traded. The 3-month trading volume is 1.82 million shares.
The consensus among analysts is that Ensysce Biosciences Inc (ENSC) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.29.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ensysce Biosciences Inc (NASDAQ:ENSC) trade information
Sporting -0.94% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the ENSC stock price touched $0.17 or saw a rise of 14.1%. Year-to-date, Ensysce Biosciences Inc shares have moved -84.11%, while the 5-day performance has seen it change -10.04%. Over the past 30 days, the shares of Ensysce Biosciences Inc (NASDAQ:ENSC) have changed -51.19%. Short interest in the company has seen 0.18 million shares shorted with days to cover at 0.54.
Ensysce Biosciences Inc (ENSC) estimates and forecasts
Figures show that Ensysce Biosciences Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -73.92% over the past 6 months, with this year growth rate of 69.51%, compared to 17.40% for the industry. Revenue growth from the last financial year stood is estimated to be -52.90%.
2 analysts offering their estimates for the company have set an average revenue estimate of 250k for the current quarter. 2 have an estimated revenue figure of 240k for the next ending quarter.
ENSC Dividends
Ensysce Biosciences Inc is expected to release its next earnings report in November this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Ensysce Biosciences Inc (NASDAQ:ENSC)’s Major holders
Insiders own 1.54% of the company shares, while shares held by institutions stand at 4.42% with a share float percentage of 4.48%. Investors are also buoyed by the number of investors in a company, with Ensysce Biosciences Inc having a total of 11.0 institutions that hold shares in the company. The top two institutional holders are PLANTE MORAN FINANCIAL ADVISORS, LLC with over 20.0 shares worth more than $10.0. As of 2024-06-30, PLANTE MORAN FINANCIAL ADVISORS, LLC held 0.0004% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund . As of Aug 31, 2024 , the former fund manager holds about 0.31% shares in the company for having 43.23 shares of worth $7280.0 while later fund manager owns 18.18 shares of worth $3060.0 as of Jun 30, 2024 , which makes it owner of about 0.13% of company’s outstanding stock.
